Regulation of the synthesis of bcl-2 protein by growth factors

Leukemia

Volumn 10, Issue 12, 1996, Pages 1925-1929

  Hu, Z B ^a   Minden, M D ^a   McCulloch, E A ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NONE   (Canada)

Author keywords

AML; Ara C; Bcl 2; Regulation; Synthesis

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HYBRID PROTEIN; INTERLEUKIN 3; PROTEIN BCL 2; SULFUR 35;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; ISOTOPE LABELING; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION;

EID: 0030479439     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Fenaux P, LeDeley MC, Castaigne S, Archambaud E, Chomienne C, Link H, Guerci A, Duater M, Daniel MT, Bowen O. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicentre randomized trial. Blood 1993; 82: 3241-3249.
2. Warrell JR, Maslak P, Eardley A, Heller G, Miller JR, Frankel SR. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 1994; 8: 929-933.
3. Ganser A, Verbeek W, Ottman OG, Maurer A, Hess U, Reutzel R, Wormann B, Hiddemann W. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia 1994; 8: 369-375.
4. Curtis JE, Messner HA, Minden MD, Lipton JH, Lockood GA, Tritchler DL, McCulloch EA. High-dose cytosine arabinoside remission induction for acute myelogenous leukemia: comparison of two regimens of remission maintenance. Leukemia 1992; 6: 1192-1198.
5. Dale DC, Davis MW, Hammond WP, Wang W, Winton W, Robinson W, Emerson W, Vincent M. A randomized controlled phase II trial of recombinant human granulocyte colony-stimulating factor (Filgastrin) for treatment of severe chronic neutropenia. Blood 1993; 81: 2486-2502.
6. Estey E, Kurzrock R, Talpaz M, Freireich E, Gutterman J, Deisseroth A. Use of CSFs in AML. In: Gale RP (ed). UCLA Symposia on Molecular and Cellular Biology. Acute Myelogenous Leukemia: Progress and Controversies. New York, 1990, pp 441-446.
7. Estey E, Thall PF, O'Brien S, Beran M, Gutterman J, Deisseroth A, Keating M. Treatment of newly-diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose Ara-C + daunorubicin: comparison with patients treated without GM-CSF. Blood 1992; 79: 2246-2255.
8. Gore SD, Donnenberg AD, Zehnbauer BA, Weng L-J, Burke PJ. Granulocyte-macrophage colony-stimulating factor (GM-CSF), given concurrently with induction therapy for acute myelogenous leukemia (AML), augments the syndrome of T-lymphocyte recovery. Leukemia 1994; 8: 409-419.
9. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 1980; 77: 2936-2940.
10. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. All-trans retinoic acid is a differentiation therapy for acute promyelocytic leukemia I. Clinical results. Blood 1990; 76: 1704-1709.
11. Buchner T, Koenigsmann M, Zuhlsdorf M, Boeckmann A, Innig G, Ludwig W-D, Heinexke A, Schultz G. Recombinant human macrophage-granulocyte colony-stimulating factor and chemotherapy in patients with acute myeloid leukemia at higher age and after relapse. Blood 1991; 78: 1190-1197.
12. Cannistra SA, DiCarlo J, Groshek P, Kanakura Y, Berg D, Mayer RJ, Griffin JD. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 1991; 5: 230-238.
13. Kufe DW, Spriggs DR. Biochemical and cellular pharmacology of cytosine arabinoside. Semin Oncol 1985; 12: 34-48.
14. Mikita T, Beardsley GP. Functional consequences of arabinosylcytosine structural lesion in DNA. Biochemistry 1988; 27: 4698-4705.
15. Major P, Egan EM, Beardsley G, Minden MD, Kufe D. Lethality of human myeloblasts correlates with incorporation of Ara-C into DNA. Proc Natl Acad Sci USA 1981; 78: 3225-3239.
16. Hu Z, Yang GS, Li M, Miyamoto N, Minden MD, McCulloch EA. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals. Leukemia 1995; 9: 789-798.
17. Hedley DW, McCulloch EA. The generation of reactive oxygen intermediates after treatment of the blasts of acute myeloblastic leukemia with cytosine arabinoside: the role of bcl-2. Leukemia 1996; 10: 1143-1149.
18. Hockenbery DM, Oitival ZN, Yin X-M, Millman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241-251.
19. Hu Z-B, Minden MD, McCulloch EA. Direct evidence for the participation of bcl-2 in the regulation of retinoic acid of the Ara-C sensitivity of leukernic stem cells. Leukemia 1995; 9: 1667-1673.
20. Lishner M, Curtis JE, Minkin S, McCulloch EA. Interaction between retinoic acid and cytosine arabinoside affecting the blast cells of acute myeloblastic leukemia. Leukemia 1989; 3: 784-788.
21. Yang GS, Minden MD, McCulloch EA, Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia. Leukemia 1994; 8: 2065-2075.
22. Miyauchi J, Kelleher CA, Wang C, Minkin S, McCulloch EA. Growth factors influence the sensitivity of leukemic stern cells to cytosine arabinoside in culture. Blood 1989; 73: 1272-1278.
23. Koistinen P, Wang C, Curtis JE, McCulloch EA. Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from Ara-C toxicity. Leukemia 1991; 5: 789-795.
24. Koistinen P, Wang C, Yang GS, Wang Y-F, Williams DE, Lyman SD, Minden MD, McCulloch EA. OCI/AML-4, an acute myeloblastic leukemia cell line: regulation and response to cytosine arabinoside. Leukemia 1991; 5: 704-711.
25. Hu Z-B, Minden MD, McCulloch EA. Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: significance for response to chemotherapy. Leukemia 1996; 10: 410-416.
26. Curtis BM, Williams DE, Broxmeyer HE, Dunn J, Farrah T, Jeffery E, Clevenger W, DeRoos P, Martin U, Friend D, Craig V, Gayle R, Price V, Cosman D, March CJ, Park LS. Enhanced hematopoietic activity of a human granulocyte/macrophage colony-stimulating factor/interleukin 3 fusion protein. Proc Natl Acad Sci USA 1991; 88: 5809-5813.
27. Wang C, Curtis JE, Minden MD, McCulloch EA. Expression of a retinoic acid receptor gene in myeloid leukemia cells. Leukemia 1989; 3: 264-269.
28. Buick RN, Till JE, McCulloch EA. Colony assay for proliferative blast cells circulating in myeloblastic leukaemia. Lancet 1977; 1: 862-863.
29. Minden MD, Buick RN, McCulloch EA. Separation of blast cell and T-lymphocyte progenitors in the blood of patients with acute myeloblastic leukemia, Blood 1979; 54: 186-195.
30. Nara N, McCulloch EA. The proliferation in suspension of the progenitors of the blast cells in acute myeloblastic leukemia. Blood 1985; 65; 1484-1493.
31. Chirgwin JM, Przybyla AE, McDonald RJ, Rutter WJ. Isolation of biochemically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979; 18: 5294-5299.
32. Maniatis T, Frisch E, Sambrook J. Molecular Cloning. Cold Spring Harbor Laboratories: Cold Spring Harbor. 1989.
33. McCulloch EA. Regulation of drug sensitivity in cultures of the blast stem cells of acute myeloblastic leukemia. In: Cacciola E, Deisseroth AB, Giustoli R (eds). Hemopoietic Growth Factors, Oncogenes and Cytokines in Clincial Hematology. Current Aspects and Future Directions. Karger: Basel, 1994, pp 137-147.